They partnered up with Tom Seemaan, mayor of New Baltimore, who arranged with various non-profit organizations and approximately 400 turkeys were given out at the Department of Public Works
They partnered up with Tom Seemaan, mayor of New Baltimore, who arranged with various non-profit organizations and approximately 400 turkeys were given out at the Department of Public Works
Cannabis reform has moved one step closer to reality at the federal level on Wednesday, with the Senate Banking Committee approving the Secure and Fair Enforcement Regulation (SAFER) Banking Act.
3 Min Read
(Reuters) - Jazz Pharmaceuticals Plc said on Wednesday it had agreed to buy GW Pharmaceuticals plc in a $7.2 billion cash-and-stock deal which will bolster its neuroscience business with the addition of a cannabis-based epilepsy treatment.
FILE PHOTO: A marijuana leaf is displayed at a medical marijuana dispensary in Seattle, Washington, in a file photo. REUTERS/Anthony Bolante
GW Pharma’s Epidiolex, the first marijuana-derived drug to be approved in the United States, generated sales of over $500 million for the U.K.-based company last year. Analysts expect sales to breach $1 billion soon.
The drug was approved in June 2018 for use in patients aged two years and older with rare childhood-onset forms of epilepsy that are among the most resistant to treatment. It has since received wider approvals, including in children of one year and older.
3 Min Read
(Reuters) - Jazz Pharmaceuticals Plc said on Wednesday it had agreed to buy GW Pharmaceuticals plc in a $7.2 billion cash-and-stock deal which will bolster its neuroscience business with the addition of a cannabis-based epilepsy treatment.
FILE PHOTO: A marijuana leaf is displayed at a medical marijuana dispensary in Seattle, Washington, in a file photo. REUTERS/Anthony Bolante
GW Pharma’s Epidiolex, the first marijuana-derived drug to be approved in the United States, generated sales of over $500 million for the U.K.-based company last year. Analysts expect sales to breach $1 billion soon.
The drug was approved in June 2018 for use in patients aged two years and older with rare childhood-onset forms of epilepsy that are among the most resistant to treatment. It has since received wider approvals, including in children of one year and older.